Adenoviral-mediated Somatostatin Receptor Subtype 2 Gene Transfer Inhibits Pancreatic Cancer Xenografts

徐彬,徐浩,李月琴,曹忠健,张欣,周天鸿
DOI: https://doi.org/10.3969/j.issn.1005-2194.2007.08.013
2007-01-01
Abstract:Objective To construct recombinant adenovirus carrying the gene of human somatostatin receptor subtype 2(SSTR2),to investigate its effect on growth of human pancreatic cancer xenografts in nude mice,and to further elucidate the underlying mechanisms.Methods The recombinant adenovirus coding for human SSTR2(Ad-SSTR2)and reporter gene LacZ(Ad-LacZ)were generated by site-specific recombination from Jun 1,2004 to Dec 10,2005.Human pancreatic cancer cell line was implanted subcutaneously into nude mice;normal saline(control group),Ad-LacZ(reporter gene control group)and Ad-SSTR2(experimental group)were injected into pancreatic cancer xenografts,respectively.The tumor volume and weight were measured.RTPCR and Western blot were used to determine the expression of SSTR2 after pancreatic cancer xenografts were infected with Ad-SSTR2.The expression level of ERK2 and ras proteins were assessed by Western blot.Results The virus titer of Ad-SSTR2 and Ad-LacZ was 6.0×1012pfu/L and 6.5×1012pfu/L,respectively.SSTR2 mRNA and protein were detected after Ad-SSTR2 infected pancreatic cancer xenografts.Growth of pancreatic cancer was significantly inhibited in the experimental group as compared with the control group.The growth inhibitory rate was 48.2%(P0.01).The significant decrease in expression of ERK2 and ras proteins was detected in the experimental group compared with the reporter gene control group and control group.Conclusion The recombinant adenovirus coding for SSTR2 has inhibitory effect on growth of human pancreatic cancer xenografts;the mechanisms are associated with down-regulation of the expression of ERK2 and ras proteins.It might be a useful treatment approach to gene therapy of human pancreatic cancer.
What problem does this paper attempt to address?